Along the same lines, efficacy of ALK inhibitors did not correlate well with NGS results in our patient, as the tumor did not respond to ceritinib and brigatinib in the third and fourth lines, despite the presence of ALK:p.V1180L and ALK:p.L1196M, respectively, which are per se sensitive to these drugs (Fig. 1; Gainor et al. 2016). Here, ALK is linked to neoplasm.